Hemispherx Biopharma Inc. (HEB)

1.80
AMEX : Health Technology
Prev Close 1.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.69 / 14.81
Avg Volume 582.80K
Exchange AMEX
Shares Outstanding 2.44M
Market Cap 4.40M
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sarepta Should Shut Up About Ebola, Focus on Job No. 1

Sarepta Should Shut Up About Ebola, Focus on Job No. 1

By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.

Hemispherx's Two Drugs, Ampligen(R) And Alferon(R) Ranked Highly In Sensitivity Testing Against MERS/SARS Coronaviruses

Hemispherx's Two Drugs, Ampligen(R) And Alferon(R) Ranked Highly In Sensitivity Testing Against MERS/SARS Coronaviruses

New Publication Compares Achievable Concentrations in Humans of Various Interferons and Other Potential Drug Treatments

Hemispherx Achieves High Ranking In Sensitivity Testing Against MERS/SARS Coronaviruses Compared To Other Drugs

Hemispherx Achieves High Ranking In Sensitivity Testing Against MERS/SARS Coronaviruses Compared To Other Drugs

New Report Compares Achievable Concentrations of Various Candidate Treatments in Humans; CDC Issues New Guidelines for Protections

Hemispherx Biopharma And Bioclones, A Leading South African Biotechnology Company, Join Forces On Novel Therapeutic Cancer Vaccine

Hemispherx Biopharma And Bioclones, A Leading South African Biotechnology Company, Join Forces On Novel Therapeutic Cancer Vaccine

Builds on Recently Issued Patent Estates of Both Companies and Basic Research / Clinical Advancement in Cancer Control

Hemispherx Biopharma And Bioclones Join Forces In Effort To Eradicate HIV/AIDS Virus Based On Recent Clinical Insights Of Wistar Institute, University Of Pennsylvania

Hemispherx Biopharma And Bioclones Join Forces In Effort To Eradicate HIV/AIDS Virus Based On Recent Clinical Insights Of Wistar Institute, University Of Pennsylvania

Patients Receiving Alpha Interferon May go Into Long Term Remission After Initial HAART (Highly Active Anti-Retroviral Therapy) Therapy is Discontinued

Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS)

Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS)

Alferon(R) N Demonstrates Antiviral Potency in Two Independent In Vitro Studies

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Hemispherx Receives New U.S. Composition Of Matter Patent Covering Ampligen(R) Formulations

Hemispherx Receives New U.S. Composition Of Matter Patent Covering Ampligen(R) Formulations

Novel Molecular Composition Provides Patent Protection for Current and Future Ampligen(R) Formulations to at Least 2029

3 Biotech Stocks Under $10 to Watch

3 Biotech Stocks Under $10 to Watch

Keep an eye on these under-$10 biotech stocks.

Hemispherx Biopharma Announces Financial Results For The Three Months Ended March 31, 2014

Hemispherx Biopharma Announces Financial Results For The Three Months Ended March 31, 2014

Notable Successes in Pandemic Flu and MERS Experimental Programs

Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro

Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro

Non-Human Primate Animal Testing Planned as This Deadly New Virus Now Reaches The United States and Southeast Asia, and Disease Incidence Accelerates

Hemispherx Biopharma Announces New Publication Enlarges The Understanding Of Ampligen(R) Safety Profile Across Diverse Animal Species And Focuses On The Unique TLR-3 Receptor/Ampligen(R) Interaction

Hemispherx Biopharma Announces New Publication Enlarges The Understanding Of Ampligen(R) Safety Profile Across Diverse Animal Species And Focuses On The Unique TLR-3 Receptor/Ampligen(R) Interaction

...Markedly Diminished Pro-Inflammatory Responses Observed in Both Non-Human Primates and in Patients With Chronic Fatigue Syndrome (CFS)

Hemispherx Biopharma Announces Financial Results For The Year Ended December 31, 2013

Hemispherx Biopharma Announces Financial Results For The Year Ended December 31, 2013

Year to Year Decrease in Net Loss

Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees

Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees

Jury Supports Hemispherx Position in Multimillion Dollar Litigation

Hemispherx Biopharma Publishes Full National Press Club Presentation On Corporate Website

Hemispherx Biopharma Publishes Full National Press Club Presentation On Corporate Website

Overview of Clinical Programs Directed Towards Development of Universal Pandemic Influenza Vaccine

A Clinical Update On The Search For A Universal Flu Vaccine: Presentation In Washington, DC On January 30, 2014 In Conjunction With The American Society For Microbiology (ASM) Biodefense Conference

A Clinical Update On The Search For A Universal Flu Vaccine: Presentation In Washington, DC On January 30, 2014 In Conjunction With The American Society For Microbiology (ASM) Biodefense Conference

Hemispherx Biopharma and Researchers With the University of Alabama at Birmingham (UAB) to Discuss Clinical Trial Studies Aimed at Developing a Universal Influenza Vaccine to Prevent Pandemic Influenza Threat

Centers For Disease Control Urges Preparation For An Active Seasonal Flu Season

Centers For Disease Control Urges Preparation For An Active Seasonal Flu Season

Hemispherx Biopharma Accelerates Program to Evaluate Ampligen(R)/FluMist(R) Combination as Potential Intranasal Influenza Vaccine Against Pandemic Flu Strains